Craniometrix vs Altria

Side-by-side comparison of AI visibility scores, market position, and capabilities

Altria leads in AI visibility (90 vs 36)

Craniometrix

EmergingHealthcare

General

SF dementia care coordination platform with Johns Hopkins MIND at Home partnership; YC $6.5M with $1.9M revenue connecting patients and caregivers through virtual care navigation for Alzheimer's management.

AI VisibilityBeta
Overall Score
D36
Category Rank
#1026 of 1167
AI Consensus
62%
Trend
stable
Per Platform
ChatGPT
46
Perplexity
42
Gemini
31

About

Craniometrix is a San Francisco-based digital health company providing virtual dementia care coordination — connecting dementia patients, family caregivers, and healthcare providers through a telemedicine platform that delivers cognitive assessment, care planning, caregiver education, and ongoing care management for Alzheimer's and related dementia conditions. Founded by CEO Nikhil Patel and backed by Y Combinator with $6-6.5 million raised from Y Combinator, Quiet Capital, and Defy.vc, Craniometrix generated $1.9 million in revenue in 2024 and partners with the Johns Hopkins MIND at Home program — a validated community-based dementia care model developed by Johns Hopkins University School of Medicine.

Full profile

Altria

LeaderConsumer Goods

Enterprise

Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.

AI VisibilityBeta
Overall Score
A90
Category Rank
#83 of 290
AI Consensus
58%
Trend
stable
Per Platform
ChatGPT
84
Perplexity
97
Gemini
99

About

Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.

Full profile

AI Visibility Head-to-Head

36
Overall Score
90
#1026
Category Rank
#83
62
AI Consensus
58
stable
Trend
stable
46
ChatGPT
84
42
Perplexity
97
31
Gemini
99
42
Claude
86
34
Grok
87

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.